Stay updated on Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page.

Latest updates to the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe Taiwan study site entry was updated from Taoyuan District, Taiwan, 33305 to Taoyuan, Taiwan, 33305. The postal code remains the same, but the city designation is clarified to Taoyuan.SummaryDifference0.0%

- Check17 days agoChange DetectedRevision: v3.5.3 has been added, replacing Revision: v3.5.2. This indicates a minor site update that does not affect page content or functionality.SummaryDifference0.0%

- Check24 days agoChange DetectedThe site’s interface revision was updated from v3.5.0 to v3.5.2 without changing the clinical study details shown on the page.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page now includes updated definitions and timeframes for primary/secondary outcomes (PFS, OS, ORR), added PK data details, and an additional Naples, Italy site.SummaryDifference1.0%

- Check67 days agoChange DetectedThe page's revision indicator was updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check88 days agoChange DetectedThe page shows a minor version update from Revision: v3.4.1 to Revision: v3.4.2; no study data or visible content were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page.